• Newron receives €3.7million under Italian government R&D support program

News & Views

Newron receives €3.7million under Italian government R&D support program

May 02 2011

Newron Pharmaceuticals SpA a research and development company focused on novel CNS and pain therapies has been advised by the Italian government’s Ministero dell’ Istruzione, dell’ Università e della Ricerca, that it is to receive a total payment of €3.7 million with immediate effect, as part of a €5 million grant for innovative R&D. In 2008 Newron was awarded the €5 million grant by the Ministry towards a €5.3 million R&D program ongoing at the company. The grant supports the research and identification of novel compounds for the treatment of diseases of the Central Nervous System. About 40% of the grant is nonreimbursable. The rest bears interest of 0.5% per year and is required to be fully repaid within 10 years from the grant date. Luca Benatti, Newron’s CEO, said: “This significant reimbursement for our R&D further strengthens our cash position and validates our continuous effort in searching for innovative Ion channel molecules for CNS diseases. This comes on the back of the private placement of SFr3.5 million (€2.7 million) completed in late December. Our operations are now funded well into 2012.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events